RL-007
RL-007 (a GABA / nicotinic modulator) is a proprietary, orally available small molecule that modulates the excitatory / inhibitory balance in the brain to improve learning and memory which has been thought shown to have pro-cognitive effects.
Preclinical evidence: RL-007 demonstrated pro-cognitive effects in healthy young animals, age-associated memory loss, and models of cholinergic-deficits. RL-007 also showed anxiolytic properties in animal models of unconditioned anxiety. It has been shown to enhance long term potentiation in rat hippocampal slices, indicating a direct action on mechanisms and brain regions involved with learning and memory processes.
Prior evidence in humans: Overall, RL-007 is a Phase 2 asset that has been evaluated in nine clinical studies – seven Phase I studies and two Phase II studies – with a total of 508 unique subjects having been dosed to date. Three of these clinical trials demonstrated improvements in verbal learning and memory, including in a large Phase II study of subjects with peripheral neuropathic pain.